<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="letter" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Our Dermatol Online</journal-id>
<journal-title>Our Dermatol Online</journal-title>
<issn pub-type="epub">2081-9390</issn>
<publisher>
<publisher-name>Our Dermatology Online</publisher-name>
<publisher-loc>Poland</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">OURD-7-494</article-id>
<article-id pub-id-type="doi">10.7241/ourd.20164.137</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letter to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Herpes zoster in patients with systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Leroux</surname>
<given-names>Maria Bibiana</given-names>
</name>
<xref ref-type="aff" rid="aff1"/>
<xref ref-type="corresp" rid="cor1"/>
</contrib>
</contrib-group>
<aff id="aff1"><italic>Centro de Referencia en Raynaud y Colagenopat&#x00ED;as, Rosario, Argentina</italic></aff>
<author-notes>
<corresp id="cor1">
<bold>Corresponding author:</bold> Dra. Maria Bibiana Leroux, E-mail: <email xlink:href="leroux_mb@hotmail.com">leroux_mb@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<year>2016</year>
</pub-date>
<volume>7</volume>
<issue>4</issue>
<fpage>494</fpage>
<lpage>495</lpage>
<history>
<date date-type="received"><day>15</day><month>03</month><year>2016</year></date>
<date date-type="accepted"><day>16</day><month>05</month><year>2016</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x000a9; Our Dermatol Online 4</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
</license>
</permissions>
</article-meta>
</front>
<body>
<sec id="sec1-1">
<title/>
<p>Sir,</p>
<p>The onset of cutaneous herpes zoster (HZ) is due to a reactivation of the varicella zoster virus and it is characterized by a painful vesicular eruption following one or more dermatomes. Post herpetic neuralgia, the most common complication could develop persisting during months or even years. The HZ it is considered the most frequent viral etiology affecting patients with systemic lupus erythematosus (SLE).</p>
<p>Recently, Borda et al. describe the epidemiological characteristics of HZ in a Brazilian population affected with SLE. Fifty five episodes of HZ were reported in 51 patients. The onset of most of them was 5 years after the SLE diagnosis and frequently during inactive or mild activity. The majority of patients show a typical distribution and a good response to treatment. Nevertheless, complications such as secondary bacterial infection and post herpetic neuralgia could be present [<xref ref-type="bibr" rid="ref1">1</xref>-<xref ref-type="bibr" rid="ref3">3</xref>].</p>
</sec>
<sec id="sec1-2">
<title>INCIDENCE</title>
<p>The HZ incidence is 1.2 - 4.9/1000 affected individuals annually. In SLE patients is significantly higher reaching 16-22/1000 annually. It is to be noticed that is associated with abnormal cytotoxicity mediated by T cells and aggravated by treatment with corticoids and immunosuppressant [<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref>]. Infection risk factors in patients with SLE in <xref ref-type="table" rid="T1">Table I</xref>.</p>
<table-wrap id="T1">
<label>Table 1</label>
<caption>
<p>Infection risk factors in patients with systemic lupus erythematosus</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="OURD-7-494-g001.tif"/>
</table-wrap>
</sec>
<sec id="sec1-3">
<title>CLINICS</title>
<p>The classic HZ topography is in general unilateral affecting one dermatome, although 20&#x0025; of patients could be extended to 3 contiguous dermatomes. Some authors classify this pattern as a disseminated HZ (Figs. <xref ref-type="fig" rid="F1">1a</xref> and <xref ref-type="fig" rid="F1">b</xref>). A varicelliform eruption could be present in non selected patients and most frequently in immunocompromised ones. In cutaneous disseminated high risk patients visceral compromise i.e. disseminated intravascular clotting, encephalitis, hepatitis, neumonitis and pancreatitis among others could complicate [<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref>].</p>
<fig id="F1">
<label>Figure 1a and b</label>
<caption>
<p>Patient with systemic lupus erythematosus and severe disseminated herpes zoster in the body affecting three dermatomes. (T 7-8-9). a- Back. b- Trunk forehead.</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="OURD-7-494-g002.tif"/>
</fig>
<p>Diagnostic methodology shown in <xref ref-type="table" rid="T2">Table 2</xref> [<xref ref-type="bibr" rid="ref1">1</xref>-<xref ref-type="bibr" rid="ref6">6</xref>].</p>
<table-wrap id="T2">
<label>Table 2</label>
<caption>
<p>Diagnostic methodology in herpes zoster</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="OURD-7-494-g003.tif"/>
</table-wrap>
</sec>
<sec id="sec1-4">
<title>TREATMENT</title>
<p>It is strongly recommended to initiate antiviral treatment within 72 hours of rash onset. The drugs above mentioned shall be maintained for 7-10 days and for 2 days after all the lesions are covered by a crust (<xref ref-type="table" rid="T3">Tabl. 3</xref>) [<xref ref-type="bibr" rid="ref1">1</xref>-<xref ref-type="bibr" rid="ref4">4</xref>].</p>
<table-wrap id="T3">
<label>Table 3</label>
<caption>
<p>Treatment with antiviral drugs</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="OURD-7-494-g004.tif"/>
</table-wrap>
<p>Primary medications for acute zoster&#x2013;associated pain include: analgesics, neuro active and anticonvulsant agents. Prompt treatment of acute zoster and its associated pain can prevent the development of post herpetic neuralgia. Hospital admission should be considered in these cases: severe symptoms, immunosuppression, significant bacterial super infection, disseminated herpes zoster, ophthalmic involvement or meningoencephalopathy involvement [<xref ref-type="bibr" rid="ref1">1</xref>-<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref>].</p>
</sec>
<sec id="sec1-5">
<title>VACCINATION</title>
<p>It was introduced in 2006. It is a live attenuated vaccine recommended for 60 years old patients comporting a reactivation risk. In these individuals a diminished HZ incidence (50&#x0025;) as well as post herpetic neuralgia has been observed (60&#x0025;). There is no clear evidence to recommend HZ vaccine in patients with SLE. There are researchers that propose that the same rule could be applied to the general population but only in those that are not medicated with immunosupressors before of after vaccination [<xref ref-type="bibr" rid="ref6">6</xref>-<xref ref-type="bibr" rid="ref7">7</xref>].</p>
</sec>
<sec id="sec1-6" sec-type="conclusion">
<title>CONCLUSION</title>
<p>Herpes zoster can be a serious problem in systemic lupus erythematosus. Its complications and its antiviral treatment are known, however, the indication of the vaccine to prevent it is not recommended in all patients.</p>
</sec>
</body>
<back>
<ref-list>
<title>REFERENCES</title>
<ref id="ref1">
<label>1</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>H-H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y-M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T-J</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>J-L</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C-H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D-Y</given-names>
</name>
</person-group>
<article-title>Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort</article-title>
<source>Clinics</source>
<year>2011</year>
<volume>66</volume>
<fpage>1177</fpage>
<lpage>82</lpage>
</nlm-citation>
</ref>
<ref id="ref2">
<label>2</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navarra</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Leynes</surname>
<given-names>MSN</given-names>
</name>
</person-group>
<article-title>Infections in systemic lupus erythematosus</article-title>
<source>Lupus</source>
<year>2010</year>
<volume>19</volume>
<fpage>1419</fpage>
<lpage>24</lpage>
</nlm-citation>
</ref>
<ref id="ref3">
<label>3</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danza</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ruiz-Irastorza</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies</article-title>
<source>Lupus</source>
<year>2013</year>
<volume>22</volume>
<fpage>1286</fpage>
<lpage>94</lpage>
</nlm-citation>
</ref>
<ref id="ref4">
<label>4</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruiz-Irastorza</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Olivares</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ruiz-Arruza</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Martinez-Berriotxoa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Egurbide</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Aguirre</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Predictors of major infections in systemic lupus erythematosus</article-title>
<source>Arthritis Res Ther</source>
<year>2009</year>
<volume>11</volume>
<fpage>R109</fpage>
</nlm-citation>
</ref>
<ref id="ref5">
<label>5</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tektonidou</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dasgupta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study 1996&#x2013;2011</article-title>
<source>Arthritis Care Res (Hoboken)</source>
<year>2015</year>
<volume>67</volume>
<fpage>1078</fpage>
<lpage>85</lpage>
</nlm-citation>
</ref>
<ref id="ref6">
<label>6</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasoto</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>ACM</given-names>
</name>
<name>
<surname>Bonfa</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Update on infections and vaccinations in systemic lupus erythematosus and Sjogren&#x2019;s syndrome</article-title>
<source>Curr Opin Rheumatol</source>
<year>2014</year>
<volume>26</volume>
<fpage>528</fpage>
<lpage>37</lpage>
</nlm-citation>
</ref>
<ref id="ref7">
<label>7</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbera</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Goldb</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Fortin</surname>
<given-names>PR</given-names>
</name>
</person-group>
<article-title>Infections in the lupus patient: perspectives on prevention</article-title>
<source>Curr Opin Rheumatol</source>
<year>2011</year>
<volume>23</volume>
<fpage>358</fpage>
<lpage>65</lpage>
</nlm-citation>
</ref>
</ref-list>
<fn-group>
<fn fn-type="supported-by">
<p><bold>Source of Support:</bold> Nil</p>
</fn>
<fn fn-type="conflict">
<p><bold>Conflict of Interest:</bold> None declared.</p>
</fn>
</fn-group>
</back>
</article>